Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00358696
Recruitment Status : Completed
First Posted : August 1, 2006
Last Update Posted : October 20, 2009
Health Canada
Information provided by:
University of British Columbia

July 28, 2006
August 1, 2006
October 20, 2009
July 2006
October 2009   (Final data collection date for primary outcome measure)
Virologic Suppression
Same as current
Complete list of historical versions of study NCT00358696 on Archive Site
HAART adherence, safety, CD4 cell count
Same as current
Not Provided
Not Provided
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus.
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression. We hypothesize that, in patients with maximal virologic suppression on a double class regimen (including two NRTIs and an NNRTI or a PI, boosted with RTV or not), a single drug substitution of didanosine for tenofovir will represent a viable strategy without any negative impact on the virologic efficacy of the regimen.

Primary objective - to determine the impact of changing part of an effective HAART regimen to tenofovir on maintenance of virologic suppression in HCV co-infected patients.

Secondary objective - to assess the safety and tolerability over 12 weeks in patients switched to tenofovir.

Research Method - This will be a single arm observational study to include 30 subjects. Patients requiring HCV treatment will be assessed and patients receiving didanosine will be clinically evaluated to determine an appropriate NRTI drug switch. Patients who are to switch the didanosine component of their regimen to tenofovir will be eligible to participate in the study and will be followed for a period of observation of up to 4 weeks. All patients will be receiving tenofovir as one capsule, once daily. The primary endpoint will be maintenance of virologic suppression between the Baseline visit and week 12 in the overall study group. Measures of adherence to HAART, safety, tolerability and CD4 cell counts will also be obtained at each study visit, and will constitute secondary study endpoints.

Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV
  • HIV Infections
Drug: tenofovir
See Detailed Description.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Be age 19 or older;
  2. Have a confirmed diagnosis of HIV infection;
  3. Have a confirmed positive HCV RNA PCR;
  4. Have two consecutive HIV RNA levels <50 copies/mL with the most recent within the past 3 months;
  5. Must not exhibit evidence of an acute illness, including an acute opportunistic infection;
  6. Must not have any evidence of grade 3-4 laboratory abnormalities;
  7. Must be able and willing to provide informed consent.

Exclusion Criteria:

  1. Be receiving investigational drug within 30 days prior to beginning this study;
  2. If female, be pregnant or breast-feeding;
  3. In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for participation for any reason.
Sexes Eligible for Study: All
19 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Brian Conway, University of British Columbia
University of British Columbia
Health Canada
Principal Investigator: Dr. Brian Conway, MD University of British Columbia
University of British Columbia
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP